Share on LinkedInShare on LinkedIn

ARTICLE · 22 NOVEMBER 2013

FTC Expands Premerger Notification Requirements To Cover Certain Pharmaceutical Patent Licenses

Jones Day
Jones Day
Contributor
Jones Day

Jones Day

Jones Day is a global law firm with more than 2,400 lawyers in 40 offices across five continents....

View firm profile
Explore more from Jones Day

On November 6, 2013, the Federal Trade Commission amended the HSR Act rules to include additional pharmaceutical patent licenses under the premerger notification and waiting period requirements.

United StatesAntitrust/Competition Law

On November 6, 2013, the Federal Trade Commission ("FTC") amended the HSR Act rules to include additional pharmaceutical patent licenses under the premerger notification and waiting period requirements (the "amended rules"). The amended rules specify that an exclusive patent license relating to a pharmaceutical product that transfers "all commercially significant rights" to the patent or part of the patent is an asset for purposes of the HSR Act. The amended rules also codify the FTC's longstanding policy that an exclusive license may be an asset for HSR Act purposes, notwithstanding the licensor's retention of certain co-rights.

FTC's current policy on exclusive patent licenses

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from